stockrow
Saturday 7 November 2026
Export DTIL’s income statement to Excel — free account
Precision BioSciences, Inc.
DTIL Healthcare Biotechnology
Precision BioSciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $34.3 million, down 50.1% from fiscal 2024.
- Revenue
- +37,272.4%
- EPS
- +85.0%
- Free cash flow
- −0.52%
- Total debt
- +0.22%
Quarter to September 2026, against a year earlier
10.75
0.88
+8.92%
Follow DTIL
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
1 | 4 | 3 | 1 | 5 | 2 | 3 | 4 | — | — |
P/E ratio |
0.00 | 1.97 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.56 | 0.38 | 0.88 | 4.10 | 3.76 | 17.85 | 26.20 | 25.26 | 25.26 | 25.26 |
Altman Z-Score |
(4.31) | (4.18) | (4.06) | (2.22) | 0.71 | (1.96) | 2.28 | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(7.20) | (8.23) | (8.14) | (3.42) | (1.44) | (7.94) | 1.20 | 0.91 | 0.91 | 3.89 |
P/Operating CF |
(4.74) | (1.39) | (5.06) | (4.71) | (18.32) | (32.23) | (28.35) | (21.29) | (21.29) | (21.29) |
Beneish M-Score |
— | 0.14 | (0.68) | 0.63 | 0.12 | 6.62 | (2.26) | 11.91 | — | — |
P/B ratio |
0.58 | 0.46 | 2.26 | 1.70 | 4.76 | 9.76 | 4.21 | 6.88 | 6.88 | 6.88 |
Price to Tangible BV |
0.59 | 0.47 | 2.31 | 1.72 | 4.87 | 10.07 | 4.26 | 7.14 | 7.14 | 7.14 |
EV/Sales |
(1.16) | (0.55) | (1.45) | (2.57) | 2.53 | 14.51 | 18.07 | 15.77 | 15.77 | 15.77 |
EV/EBITDA |
0.80 | 1.70 | 1.97 | 1.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.60 | 0.65 | 0.84 | 1.41 | (26.97) | (4.03) | (5.66) | (3.32) | (3.32) | (3.32) |
EV/FCF |
0.60 | 0.65 | 0.82 | 1.31 | (18.40) | (3.81) | (4.20) | (2.60) | (2.60) | (2.60) |
Quick Ratio |
12.97 | 5.78 | 2.35 | 3.19 | 4.01 | 2.33 | 6.75 | 7.37 | 6.83 | 11.25 |
Current Ratio |
13.32 | 6.34 | 2.73 | 3.34 | 4.50 | 2.46 | 7.19 | 8.22 | 6.99 | 11.32 |
Net Debt/EBITDA |
1.86 | 2.87 | 3.24 | 3.12 | 4.84 | 0.81 | 2.21 | 2.27 | 3.08 | 11.41 |
Debt/Assets |
14.51% | 16.37% | 0.00% | 9.33% | 1.17% | 5.72% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.24 | 0.40 | 0.00 | 0.37 | 0.03 | 0.19 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.24 | 0.46 | 0.24 | 0.11 | 0.64 | 0.13 | 0.12 | 0.10 | 0.08 | 0.08 |
Operating CF/Net income |
1.44 | (8.15) | 1.37 | 0.41 | 0.35 | 0.80 | 0.76 | 1.12 | 1.15 | (11.18) |
Capex/Depreciation |
(0.31) | (0.06) | (0.28) | (0.38) | (0.57) | (0.51) | (4.64) | (6.06) | (3.55) | 0.00 |
Interest Coverage |
(36.67) | (14.68) | (19.61) | (56.08) | (298.30) | (133.61) | (479.14) | (25.55) | (25.20) | (30.98) |
| (61.52%) | 19.05% | (154.66%) | (147.28%) | (45.14%) | (119.30%) | (104.20%) | (677.86%) | 135.60% | 53.02% | |
| (31.45%) | 4.84% | (30.82%) | (49.65%) | (16.92%) | (56.57%) | (49.69%) | (43.58%) | (24.67%) | (9.64%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(41.10%) | 8.62% | (66.14%) | (73.81%) | (20.28%) | (111.43%) | (45.02%) | (37.51%) | (33.35%) | (9.21%) |
Average Days of Receivables |
0.00 | 1.22 | 6.75 | 10.47 | 1.54 | 150.30 | 15.84 | 17.54 | 1.24 | 20.08 |
Research and Development Expense of Revenue |
158.10% | 86.70% | 109.54% | 183.77% | 99.75% | 403.79% | 370.61% | 414.61% | 313.45% | 129.75% |
Selling, General and Administrative Expense of Revenue |
94.09% | 51.38% | 80.22% | 164.49% | 34.34% | 148.45% | 121.53% | 125.64% | 123.63% | 86.97% |
Intangible Assets out of Total Assets |
0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
29.73% | 18.35% | 28.81% | 76.49% | 14.29% | 56.77% | 40.20% | 22.54% | 6.46% | 0.00% |
Graham Net Nets |
1.06 | 0.58 | (0.11) | 0.21 | 0.10 | 0.00 | 0.17 | 0.06 | 0.06 | 0.06 |
Graham Number |
0.00 | 18.93 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(123.08%) | 50.66% | (144.79%) | (119.78%) | (7.03%) | (25.08%) | (22.70%) | (16.75%) | (16.75%) | (16.75%) |
Free Cash Flow Yield |
(124.59%) | (225.60%) | (202.38%) | (47.72%) | (3.67%) | (21.32%) | (16.42%) | (24.01%) | (24.01%) | (24.01%) |
Revenue per Share |
2.67 | 10.05 | 12.69 | 8.57 | 59.12 | 14.02 | 15.90 | 20.72 | 12.24 | 0.14 |
Operating CF per Share |
(5.13) | (8.55) | (21.90) | (15.62) | (5.55) | (50.43) | (50.79) | (98.46) | (45.63) | 1.84 |
Capex per Share |
(0.05) | (0.03) | (0.57) | (1.13) | (2.97) | (2.90) | (17.64) | (27.15) | (10.41) | 0.00 |
Free Cash Flow per Share |
(5.18) | (8.58) | (22.46) | (16.75) | (8.52) | (53.34) | (68.43) | (125.62) | (56.04) | 1.84 |
Cash per Share |
9.01 | 12.63 | 30.38 | 64.70 | 73.51 | 51.83 | 129.36 | 196.45 | 118.56 | 1.86 |
Shareholders Equity per Share |
7.19 | 8.25 | 4.91 | 20.63 | 46.65 | 25.64 | 98.92 | 76.07 | (49.78) | (0.09) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
7.19 | 8.25 | 4.91 | 20.63 | 46.65 | 25.64 | 98.92 | 76.07 | (49.78) | (0.09) |
Free Cash Flow |
(66.48) | (58.66) | (86.28) | (49.07) | (16.66) | (92.42) | (95.68) | (65.99) | (29.68) | 92.27 |
Working Capital |
109.83 | 80.01 | 86.37 | 139.44 | 125.77 | 62.74 | 166.74 | 101.60 | 55.13 | 86.06 |
Capital Expenditures |
(0.63) | (0.21) | (2.17) | (3.32) | (5.80) | (5.03) | (24.67) | (14.26) | (5.51) | (2.07) |
Net Current Asset Value |
56.57 | 14.99 | (4.56) | 21.37 | 41.42 | (0.17) | 96.75 | 17.04 | (34.72) | (8.76) |
EV/EBIT |
0.76 | 1.45 | 1.62 | 1.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.02 | 0.00 | 0.04 | 0.13 | 0.05 | 0.21 | 1.11 | 1.31 | 0.85 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.45 | 1.26 | 1.22 | 0.73 | 0.40 | 0.28 | 0.13 | 0.11 | 0.19 | 0.18 |
Cash ROIC |
(28.87%) | (35.55%) | (63.66%) | (18.03%) | (7.02%) | (64.71%) | (29.98%) | (46.09%) | (81.48%) | 104.06% |
Accounts Receivable Turnover |
0.00 | 121.59 | 60.12 | 41.55 | 22.03 | 4.43 | 29.89 | 39.94 | 31.78 | 34.39 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | — | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | — | — | — | — | — | — |
Average Receivables |
— | 0.57 | 0.81 | 0.60 | 5.24 | 5.48 | 0.74 | 0.27 | 0.20 | 0.20 |
Average Payables |
0.80 | 2.14 | 1.81 | 0.90 | 0.97 | 1.41 | 2.13 | 2.01 | 1.55 | 1.55 |
Average Assets |
145.40 | 148.08 | 198.98 | 224.83 | 180.83 | 192.70 | 186.92 | 105.64 | 85.55 | 85.55 |
Average Common Equity |
74.32 | 37.63 | 39.65 | 75.80 | 67.80 | 91.37 | 89.13 | 6.79 | (15.56) | (15.56) |
Columns are period end dates · fundamentals updated 5 Nov 2026